Top Markets
Coin of the day
China Medicine Corp. China Medicine Corp.

China Medicine Corp.

CHME
Rangering i aksjer #38472
China Medicine Corporation produces and distributes prescription and over the... China Medicine Corporation produces and distributes prescription and over the counter drugs, traditional Chinese medicine products, herbs and dietary-supplements, medical devices, and medical formulations in China. The company offers various products for applications, including oncology, high blood pressure, and removal of toxins from food and animal feeds. It provides products that treat stagnation of the heart blood, obstruction of qi in the chest, cardiodynia, headache, and dysmenorrhea; upper respiratory tract infection, acute faucitis, acute tonsillitis, acute gastroenteritis, etc.; acute and chronic hepatitis, deferment hepatitis, cholecystitis, etc.; irregular menstruation, dysmenorrhea, and amenorrhea; anemia and deficiency of vital energy; palpitation, dizziness, and fatigue; and cerebral arteriosclerosis and ischemic stroke. The company distributes its products through a sales network in China. The company was formerly known as Lounsberry Holdings III, Inc. and changed its name to China Medicine Corporation in May 2006. China Medicine Corporation was founded in 2005 and is based in Guangzhou, China.
Aksjekurs
$0.0406
Sist synkronisert: 2026-08-13
Markedsverdi
$962.71K
Endring (1 dag)
0.00%
Endring (1 år)
6,666.67%
Land
CN
Handel China Medicine Corp. (CHME)

Kategori

Antall utestående aksjer for China Medicine Corp. (CHME)
Antall utestående aksjer per August 2026: 0
Ifølge China Medicine Corp. sine siste økonomiske rapporter og aksjekurs er antall utestående aksjer nå 0. Ved slutten av August 2026 hadde selskapet 0 utestående aksjer. Antallet utestående aksjer påvirkes vanligvis av aksjesplitt og tilbakekjøp.
Historikk over utestående aksjer for China Medicine Corp. (CHME) fra 2026 til 2026
Utestående aksjer ved utgangen av hvert år
År Utestående aksjer Endre
Ikke nok data for de angitte datoene.
Utestående aksjer for lignende selskaper eller konkurrenter